Matching‐adjusted indirect comparison of bleeding outcomes in severe haemophilia A: Comparing valoctocogene roxaparvovec gene therapy, emicizumab prophylaxis, and FVIII replacement prophylaxis
emicizumab
Factor VIII
haemophilia A
Hemorrhage
Genetic Therapy
16. Peace & justice
Hemophilia A
AAV5-hFVIII-SQ
FVIII prophylaxis
matching-adjusted indirect comparison (MAIC)
Antibodies, Bispecific
Hemarthrosis
Humans
valoctocogene roxaparvovec
DOI:
10.1111/hae.14818
Publication Date:
2023-06-24T21:35:06Z
AUTHORS (11)
ABSTRACT
Abstract Introduction Head‐to‐head evaluation of valoctocogene roxaparvovec, the first gene therapy approved for haemophilia A, with emicizumab is not available. Therefore, phase 3 trial data were indirectly compared. Aim To compare bleeding rates in trials evaluating 6 × 10 13 vg/kg roxaparvovec (GENEr8‐1; NCT03370913), 1.5 mg/kg dosed every week (HAVEN 3; NCT02847637), and FVIII prophylaxis (270–902) participants severe A (FVIII ≤1 IU/dL). Methods Valoctocogene versus as used 270–902 cross‐trial comparisons performed using matching‐adjusted indirect comparison (MAIC). Individual participant from GENEr8‐1 weighted to equalise aggregate baseline characteristics HAVEN 3. After MAIC weighting, annualised (ABR) proportions without bleeds compared treated bleeds, all joint spontaneous bleeds. Results ABR was statistically significantly lower than (rate ratio [95% CI], .55 [.33–.93]). Additionally, higher had no (odds 2.75 [1.20–6.31]) (3.25 [1.53–6.90]) emicizumab. When mainly standard half‐life regimens 270–902, mean ABRs (except bleeds) lower, reported 0 outcomes Conclusion provided generally probability including Emicizumab more effective 270–902.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (23)
CITATIONS (5)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....